Literature summary extracted from

Marder, V.J.
Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator (2008), Thromb. Res., 122 Suppl 3, S9-S15.

Application

EC Number	Application	Comment	Organism
3.4.21.68	medicine	in comparison with t-PA, plasmin shows a distinct benefit-to-risk advantage. Plasmin is equally effective as t-PA in thrombolysis and may be superior for treating thrombi in totally-occluded vessels. Whereas t-PA causes bleeding from vascular trauma sites in animals when infused at dosages used for thrombolysis (0.5-1 mg/kg), plasmin exhibits safety at therapeutic dosages. Plasmin can be used at several fold higher concentrations than is needed for thrombolysis, thereby providing a significant safety margin that is not attainable for t-PA	Oryctolagus cuniculus
3.4.21.68	medicine	plasmin is a suitable alternative to t-PA as it causes less bleeding but has equivalent or greater thrombolytic efficacy	Homo sapiens

Cloned(Commentary)

EC Number	Cloned (Comment)	Organism
3.4.21.68	-	Homo sapiens

Organism

EC Number	Organism	UniProt	Comment	Textmining
3.4.21.68	Homo sapiens	-	-	-
3.4.21.68	Oryctolagus cuniculus	-	-	-

Substrates and Products (Substrate)

EC Number	Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
3.4.21.68	plasminogen + H2O	-	Oryctolagus cuniculus	plasmin + ?	-	?
3.4.21.68	plasminogen + H2O	patients suffering intracranial hemorrhage or cerebral infarction after receiving 100 mg t-PA for acute myocardial infarction	Homo sapiens	plasmin + ?	-	?

Synonyms

EC Number	Synonyms	Comment	Organism
3.4.21.68	t-PA	-	Homo sapiens
3.4.21.68	t-PA	-	Oryctolagus cuniculus
3.4.21.68	Tissue plasminogen activator	-	Homo sapiens
3.4.21.68	Tissue plasminogen activator	-	Oryctolagus cuniculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)